Grimes & Company, Inc. Mersana Therapeutics, Inc. Transaction History
Grimes & Company, Inc.
- $3.66 Billion
- Q3 2024
A detailed history of Grimes & Company, Inc. transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Grimes & Company, Inc. holds 14,998 shares of MRSN stock, worth $29,696. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,998
Previous 14,998
-0.0%
Holding current value
$29,696
Previous $30,000
6.67%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding MRSN
# of Institutions
121Shares Held
116MCall Options Held
233KPut Options Held
457K-
Eco R1 Capital, LLC San Francisco, CA19.4MShares$38.3 Million1.59% of portfolio
-
Nextech Invest Ag12.1MShares$23.9 Million3.72% of portfolio
-
Vr Adviser, LLC New York, NY11.3MShares$22.4 Million2.22% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$17.2 Million2.94% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$16.6 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $192M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...